Utah Medical ProductsUTMD.OValuation Analysis

As of Oct 16, 2026, Utah Medical Products (UTMD.O) trades at a P/E of 22.60x, P/B of 1.95x, P/S of 6.57x, and a dividend yield of 1.24%.
Longitudinal percentile comparison: P/E sits at the 69th percentile over the trailing 10Y window (vs. 100th percentile over 3Y); P/B sits at the 25th percentile over the trailing 10Y window (vs. 84th percentile over 3Y); P/S sits at the 50th percentile over the trailing 10Y window (vs. 100th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 47th percentile within its industry and the 58th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.76%, ranking at the 66th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 43.7 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 4.76% total shareholder yield, 1.24% is paid out as dividends and roughly 3.52% is implied to come from buybacks — both channels are meaningfully in play. Utah Medical Products operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.